AXL expression has been observed in 35% of AML patient samples and has been correlated with shorter OS in AML patients.128,129 Inhibition of AXL in AML cells via bemcentinib (BGB324), a selective AXL inhibitor (Fig. 3), inhibited cell survival regardless of FLT3 status and promoted sensitivity to cytarabine and doxorubicin and inhibition showed promising effects in mice with FLT3-ITD AML xenografts.129 Based on efficacy in preclinical studies, bemcentinib was entered into several clinical trials. Here, FLT3 is linked to acute myeloid leukemia.